Immune cell distribution change after radiation therapy in patients with advanced head and neck cancer
Not Applicable
- Conditions
- Oligoprogressive head and neck cancerCancer - Head and neck
- Registration Number
- ACTRN12622000495729
- Lead Sponsor
- Olivia Newton-John Cancer Research Institute (ONJCRI)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
head and neck SCC with oligo-progression to 1-10 extracranial lesions, lesion size no more than 5cm and involving no more than 3 organs.
Sites of oligo-progressive disease can be targetable with SBRT and safely treated
At least one tumour lesion can be observed and will not be in the beam path of SBRT, and the observed lesion must be measurable by the criteria of RECIST version 1.1
Exclusion Criteria
Metastatic or locoreginal disease disease invades the GI tract or large blood vessels
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method